DK1690549T3 - Immunoterapeutisk middel, som anvendes til den kombinerede behandling af tuberkulose sammen med andre lægemidler - Google Patents

Immunoterapeutisk middel, som anvendes til den kombinerede behandling af tuberkulose sammen med andre lægemidler

Info

Publication number
DK1690549T3
DK1690549T3 DK04791401T DK04791401T DK1690549T3 DK 1690549 T3 DK1690549 T3 DK 1690549T3 DK 04791401 T DK04791401 T DK 04791401T DK 04791401 T DK04791401 T DK 04791401T DK 1690549 T3 DK1690549 T3 DK 1690549T3
Authority
DK
Denmark
Prior art keywords
tuberculosis
drugs
combined treatment
immunotherapeutic agent
agent used
Prior art date
Application number
DK04791401T
Other languages
Danish (da)
English (en)
Inventor
Iglesias Pere Joan Cardona
Riera Isabel Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Application granted granted Critical
Publication of DK1690549T3 publication Critical patent/DK1690549T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04791401T 2003-10-31 2004-10-29 Immunoterapeutisk middel, som anvendes til den kombinerede behandling af tuberkulose sammen med andre lægemidler DK1690549T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302551A ES2231037B1 (es) 2003-10-31 2003-10-31 Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
PCT/ES2004/000482 WO2005042013A1 (es) 2003-10-31 2004-10-29 Agente immunoterápico útil para el tratamento combinado de la tuberculosis en associación con otros fármacos

Publications (1)

Publication Number Publication Date
DK1690549T3 true DK1690549T3 (da) 2009-08-17

Family

ID=34530979

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04791401T DK1690549T3 (da) 2003-10-31 2004-10-29 Immunoterapeutisk middel, som anvendes til den kombinerede behandling af tuberkulose sammen med andre lægemidler

Country Status (20)

Country Link
US (1) US8246944B2 (de)
EP (1) EP1690549B1 (de)
JP (1) JP4998988B2 (de)
KR (1) KR101146469B1 (de)
CN (1) CN100490894C (de)
AT (1) ATE428442T1 (de)
AU (1) AU2004285305B2 (de)
BR (1) BRPI0415695B8 (de)
CA (1) CA2543659C (de)
DE (1) DE602004020663D1 (de)
DK (1) DK1690549T3 (de)
ES (2) ES2231037B1 (de)
IL (1) IL175030A (de)
MA (1) MA28121A1 (de)
NZ (1) NZ546715A (de)
PL (1) PL1690549T3 (de)
PT (1) PT1690549E (de)
RU (1) RU2341287C2 (de)
WO (1) WO2005042013A1 (de)
ZA (1) ZA200604234B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
WO2007132790A1 (ja) * 2006-05-12 2007-11-22 National University Corporation Hokkaido University 細菌菌体成分を含む脂質膜を有するリポソーム
ES2307402B1 (es) * 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2471511A1 (de) 2011-01-04 2012-07-04 Archivel Farma, SL Zur Behandlung oder Vorbeugung von Tuberkulose geeignete Liposomformulierung
CN107296793A (zh) * 2011-01-04 2017-10-27 阿尔西维尔法尔玛公司 适于治疗或预防结核的脂质体制剂
BR112014017217B1 (pt) * 2012-01-12 2023-01-17 Archivel Farma, S.L Agente e composição farmacêutica
ES2758400B2 (es) 2018-11-02 2021-01-20 Univ Granada Nanoparticulas biomimeticas mediadas por mamc
CN120456894A (zh) 2021-10-14 2025-08-08 爱琴韦尔制药公司 用于治疗活动性结核病的脂质体制剂
WO2025191183A1 (en) 2024-03-15 2025-09-18 Archivel Farma S.L. Liposome formulations for the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3125598A1 (de) * 1981-06-30 1983-01-13 Mahle Gmbh, 7000 Stuttgart Einrichtung zur druckbeaufschlagung des presszylinders einer druckgiessmaschine
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
JPS624701A (ja) * 1985-06-29 1987-01-10 Maruyama Chisato リポ多糖体及びその製造法
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
AU766093B2 (en) * 1998-10-08 2003-10-09 Statens Serum Institut Tuberculosis vaccine and diagnostic reagents based on antigens from the mycobacterium tuberculosis cell
RU2153354C1 (ru) * 1999-03-31 2000-07-27 Московский городской научно-практический центр борьбы с туберкулезом Вакцина против туберкулеза
US6664096B2 (en) * 2000-12-08 2003-12-16 Ying Zhang Methods for improved diagnosis and treatment of mycobacterial infections
US7105170B2 (en) * 2001-01-08 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services Latent human tuberculosis model, diagnostic antigens, and methods of use
EP1379529A2 (de) * 2001-03-16 2004-01-14 Sarawak Medichem Pharmaceuticals, Inc. Pyranocoumarin verbindungen als neue pharmakophore mit anti-tb activität
CA2453173C (en) 2001-07-04 2013-12-10 Health Protection Agency Mycobacterial antigens expressed during latency
WO2003018053A1 (en) 2001-08-22 2003-03-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine against mycobacterial-induced diseases
WO2003063897A1 (en) 2002-01-29 2003-08-07 Modi, Rajiv, Indravadan Method of providing prophylaxis for tuberculosis in hiv positive individuals
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
DE102004053141A1 (de) * 2004-11-03 2006-05-04 Schülke & Mayr GmbH Desinfektionsmittel mit verbesserter Wirksamkeit gegen Mykobakterien

Also Published As

Publication number Publication date
US20070269501A1 (en) 2007-11-22
WO2005042013A1 (es) 2005-05-12
CA2543659A1 (en) 2005-05-12
IL175030A0 (en) 2006-08-20
KR20060126963A (ko) 2006-12-11
CN1874785A (zh) 2006-12-06
MA28121A1 (fr) 2006-08-01
EP1690549A1 (de) 2006-08-16
ES2231037A1 (es) 2005-05-01
ES2325835T3 (es) 2009-09-21
CA2543659C (en) 2012-04-17
HK1098362A1 (zh) 2007-07-20
RU2341287C2 (ru) 2008-12-20
BRPI0415695A (pt) 2006-12-26
BRPI0415695B8 (pt) 2021-05-25
RU2006118795A (ru) 2007-12-10
EP1690549B1 (de) 2009-04-15
BRPI0415695B1 (pt) 2019-09-10
PT1690549E (pt) 2009-07-20
AU2004285305B2 (en) 2009-11-12
ES2231037B1 (es) 2005-12-16
ATE428442T1 (de) 2009-05-15
IL175030A (en) 2012-02-29
US8246944B2 (en) 2012-08-21
PL1690549T3 (pl) 2010-01-29
JP4998988B2 (ja) 2012-08-15
BRPI0415695A8 (pt) 2019-01-15
KR101146469B1 (ko) 2012-05-21
AU2004285305A1 (en) 2005-05-12
DE602004020663D1 (de) 2009-05-28
CN100490894C (zh) 2009-05-27
JP2007509910A (ja) 2007-04-19
ZA200604234B (en) 2007-11-28
NZ546715A (en) 2008-05-30

Similar Documents

Publication Publication Date Title
SE0301700D0 (sv) Novel compounds
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
NO20081844L (no) Terapeutiske forbindelser
NO20050607L (no) Fremgangsmate og innretning for tildeling av CO
AR039644A1 (es) Composicion farmaceutica que comprende un androgeno, un mejorador de hsieh y un agente espesante.
NO20064584L (no) Tetrahydropyridoindolderivater
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
NO20091955L (no) Antivirale sammensetninger, og fremgangsmater for anvendelse
CL2007001917A1 (es) Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras.
CY1108453T1 (el) Διαδικασια για την παρασκευη επλερενονης
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
PL376176A1 (en) Solid preparation
NO20073813L (no) Kladribinregime for behandling av multippel sklerose
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme
IL175030A0 (en) Immunotherapic agent which is used for the combined treatment of tuberculosis together with other pharmaceuticals
AR055755A1 (es) Derivado de bencimidazol, procesos de obtencion, composiciones farmaceuticas y usos.
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone